Olaf Kelber

Olaf Kelber

Auto-generated profile, based on publicly available information

Olaf Kelber

Innovation and Development, Phytomedicine Supply and Development Centre, Bayer Consumer Health Care, Steigerwald Arzneimittel GmbH, Havelstraße 5, 64295 Darmstadt, Germany

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2012 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
CVCica Vissiennon
Cica Vissiennon
KNKaren Nieber
Karen Nieber
OKOlaf Kelber
Olaf Kelber
VBVeronika Butterweck
Veronika Butterweck

1 December 2010 in Phytomedicine
Verified
Journal Article
Closed access
GBGabriel Bonaterra
Gabriel Bonaterra
EHE.U. Heinrich
E.U. Heinrich
OKO. Kelber
O. Kelber
DWD. Weiser
D. Weiser
JMJ. Metz
J. Metz
RKR. Kinscherf
R. Kinscherf

18 May 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
EPEva-Maria Pferschy-Wenzig
Eva-Maria Pferschy-Wenzig
MPManuela Pausan
Manuela Pausan
KAKarin Ardjomand-Woelkart
Karin Ardjomand-Woelkart
SRStefanie Röck
Stefanie Röck
Ramy AmmarRamy Ammar
Ramy Ammar
Rudolf BauerRudolf Bauer
Rudolf Bauer
Background: Various neurocognitive and mental health-related conditions have been associated with the gut microbiome, implicating a microbiome–gut–brain axis (MGBA). The aim of this systematic review was to identify, categorize, and review clinical evidence supporting medicinal plants for the treatment of mental disorders and studies on their interactions with the gut microbiota. Methods: This review included medicinal plants for which clinical studies on depression, sleeping disorders, anxiety, or cognitive dysfunction as well as scientific evidence of interaction with the gut microbiome were available. The studies were reported using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Results: Eighty-five studies met the inclusion criteria and covered thirty mental health-related medicinal plants with data on interaction with the gut microbiome. Conclusion: Only a few studies have been specifically designed to assess how herbal preparations affect MGBA-related targets or pathways. However, many studies provide hints of a possible interaction with the MGBA, such as an increased abundance of health-beneficial microorganisms, anti-inflammatory effects, or MGBA-related pathway effects by gut microbial metabolites. Data for Panax ginseng, Schisandra chinensis, and Salvia rosmarinus indicate that the interaction of their constituents with the gut microbiota could mediate mental health benefits. Studies specifically assessing the effects on MGBA-related pathways are still required for most medicinal plants.

24 November 2013 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
CWChristopher Weidner
Christopher Weidner
SWSylvia J. Wowro
Sylvia J. Wowro
AFAnja Freiwald
Anja Freiwald
VKVitam Kodelja
Vitam Kodelja
HAHeba Abdel‐Aziz
Heba Abdel‐Aziz
SSSascha Sauer
Sascha Sauer

1 November 2006 in Phytomedicine
Verified
Journal Article
Closed access
HAH.P.T. Ammon
H.P.T. Ammon
OKO. Kelber
O. Kelber
SOS.N. Okpanyi
S.N. Okpanyi